Kenji Itoh

Kenji Itoh is a clinical oncologist specializing in thyroid and other endocrine malignancies with extensive experience evaluating kinase inhibitors including sorafenib and lenvatinib in Japanese patient cohorts. His work has helped define safety and efficacy profiles of systemic therapies specifically in Asian populations with thyroid cancer. He has contributed to regional clinical trials examining dosing, tolerability, and biomarker correlates in differentiated thyroid cancer. His research informs treatment guidelines in Japan and across East Asia.